Background-Statin therapy reduces adverse outcomes, with a minimal decrease in vessel stenosis. Magnetic resonance imaging (MRI) noninvasively detects atherosclerotic plaque (AP) reduction. We hypothesized that statin-induced AP regression can be monitored by MRI and detected earlier than previously reported and is significantly associated with its lipid-lowering effect. Methods and Results-APs in thoracic aorta were measured by combined surface/transesophageal MRI in 27 patients (treated with simvastatin 20 to 80 mg daily) before and after 6 months of therapy. AP volume and luminal dimensions were measured from 6 cross sections used to construct a 2.4-cm 3D volume of the aorta that included plaque and lumen. Method reproducibility was studied in 10 patients imaged twice, 1 week apart. AP volume was reduced from 3.3Ϯ0.1.4 to 2.9Ϯ1.4 cm 3 at 6 months (PϽ0.02), whereas luminal volume increase was less accentuated (from 12.0Ϯ3.9 to 12.2Ϯ3.7 cm 3 , PϽ0.06). LDL cholesterol decreased by 23% (from 125Ϯ32 to 97Ϯ27 mg/dL, PϽ0.05) in 6 months. AP regression (plaque volume/area reduction) was significantly related to LDL cholesterol reduction (PϽ0.02 and PϽ0.005, respectively), and luminal volume increase was inversely related to LDL cholesterol reduction (PϽ0.04). Plaque volume measurement was highly reproducible (intraclass correlation Rϭ0.98 and variabilityϭ4.8%). Intraobserver (0.91) and interobserver (0.81) concordances were documented for plaque volume assessment. Conclusions-AP regression and reverse remodeling can be detected accurately by MRI 6 months after statin therapy initiation, and it is strongly associated with LDL cholesterol reduction. (Circulation. 2004;110:2336-2341.) 
A therosclerosis remains the leading cause of death in industrialized societies, and its incidence is projected to increase worldwide in the next 2 decades. 1 The benefits of statin therapy on atherosclerosis have been clearly established in several clinical trials. Typically, sustained statin therapy induces LDL cholesterol (LDL-C) reductions of 30% to 40%, which translate into mortality reductions of 25% to 30%. [2] [3] [4] [5] However, the clinical benefits of decreased clinical events are not proportional to parallel reductions in vessel stenoses. 6 This apparent discrepancy can be explained by the results of previous studies documenting plaque regression in the face of minor alterations in luminal stenosis through reverse vessel remodeling. 7 Although plaque regression is considered to be a significant determinant of statin-induced clinical benefits in both primary and secondary prevention, 8 its mechanisms and time course remain incompletely understood.
Direct visualization of atherosclerotic plaques by imaging techniques 9 has the potential to provide important insights into the pathophysiology of plaque regression secondary to lipid-lowering therapy. Results from clinical trials using carotid ultrasound 10, 11 and intravascular ultrasound 12 and prospective studies using MRI 13 suggest that plaque regression can be documented only after at least 1 year of statin therapy. Conversely, pathological studies have documented statin-induced changes in plaque composition as early as 3 months after therapy initiation. 14 More recently, a small trial using intravenous apolipoprotein A-I Milano to raise HDL cholesterol levels has documented plaque regression by intravascular ultrasound after only 6 weeks of therapy. 15 These observations challenge the current paradigm of atherosclerosis as a chronic process that evolves slowly and requires prolonged lipid-lowering therapy to regress.
They have also refocused attention on the mechanisms of statin-induced atherosclerotic plaque regression, which have not been entirely elucidated. Although most previous studies have attributed statin-induced plaque regression to changes in LDL 10, 11, 16 and/or HDL 6, 15 cholesterol, plaque regression has also been documented in response to other types of therapies that do not directly influence lipid levels. [17] [18] [19] Moreover, although statin-induced lipid lowering and clinical benefits may occur in a matter of weeks, 20 statin-mediated plaque regression has been measured in terms of years after the initiation of statin therapy. 6,8,10 -13,16 These discrepancies highlight the need for greater insight into the mechanisms and time course of statin-induced plaque regression.
MRI, as a noninvasive technique that allows for serial visualization of atherosclerotic plaque morphology, is particularly suited to monitor atherosclerosis in humans and animal models. 9, 13, 21, 22 Paramount to the utilization of MRI to monitor atherosclerosis, however, is the demonstration that the method is both accurate and reproducible, 9 features that are in large part dependent on the ratio of MRI signal to background noise. Transesophageal MRI (TEMRI) is a novel technique that can be combined with standard surface MRI to enhance the ability to image the aortic arch and proximal descending aorta, 23, 24 where aortic atherosclerotic plaques are frequently found. We hypothesized that statin-induced plaque regression can be monitored clinically by the combined transesophageal and surface-coil MRI approach, is significantly associated with its lipid-lowering effect, and can be detected noninvasively earlier than previously reported.
Methods

Study Design
In this prospective study, after screening, 59 patients were deemed eligible, and 27 agreed to be enrolled in the study. We included patients with documented atherosclerosis in at least 1 vascular territory: at least moderate (Ͼ3.9 mm) aortic atherosclerosis seen on transesophageal echocardiography, moderate coronary artery disease (Ͼ50% lesion) in at least 1 coronary artery seen at cardiac catheterization, Ͼ50% carotid lesion seen on ultrasound, or documented peripheral vascular disease. These patients are enrolled in a randomized trial testing the effects of high-versus low-dose statin (20 versus 80 mg of simvastatin) therapy on aortic plaque regression. We excluded patients with pacemakers, automated implanted cardioverter defibrillators, aneurysm clips, abnormal nasopharyngeal anatomy, active peptic ulcer disease, severe dysphagia, abnormally elevated baseline liver transaminases (Ͼ2ϫ normal), a clinically significant medical event within 3 months before study entry, decompensated congestive heart failure, or inability to give informed consent. Diabetes was defined as fasting blood sugar level Ͼ126 mg/dL or use of antiglycemic therapy. Hypertension was defined as a blood pressure Ͼ140 mm Hg systolic and/or 90 mm Hg diastolic or use of antihypertensive medications. Smoking history was considered if a subject smoked at any time in the past or did so currently. Positive family history for coronary artery disease was considered when subjects reported physician-diagnosed coronary artery disease or myocardial infarction in a parent, grandparent, or sibling before age 60. A history of myocardial infarction or stroke was self-reported by the patient, on the basis of a physician-based diagnosis. All patients were using statin therapy at baseline, and patients agreed to be switched to simvastatin. Other laboratory studies, including creatine kinase, aspartate aminotransferase, alanine aminotransferase, and serum creatinine levels, were obtained every 3 months; in addition, TEMRIs were obtained at baseline and 6 months. Patients were enrolled in the study after providing written consent according to The Johns Hopkins Committee on Clinical Investigation and General Clinical Research Center guidelines.
MRI Protocol
MRI of the thoracic aorta was performed in a 1.5-T (40 mT/m) Sigma (General Electric) magnet using a standard flex coil (General Electric) and a specially designed 2-element cardiac phased-array coil positioned on the chest wall (both 13ϫ16 inches in dimension). We used a TEMRI receiver coil (Intercept Esophageal MR Coil, Surgi-Vision) in the remaining coil position (approximate diameter 8F). It was positioned in the esophagus through a 9F to 10F nasogastric tube by an experienced physician. ECG-gated fast spin-echo and inversion recovery radiofrequency pulses were used to produce a black-blood double oblique sagittal image (candy cane view) of the thoracic aorta. A chemical shift suppression pulse was used to suppress the signal from perivascular fat for proton densityweighted (PDW) images. The thickest plaque was identified in the aorta, and through this area, 6 contiguous images (to reduce submillimeter errors in matching of the images at different time points) with a 4-mm slice thickness were obtained (1 slice/breath hold). We imaged perpendicular to the vessel wall (using the double-inversion recovery pulse sequence) with T2-weighted (T2W) and PDW techniques during breath holds (11 to 15 seconds for PDW and 15 to 20 seconds for T2W images). All participants were able to complete the study, and repetitive breath holds were not required. Additional imaging parameters were as follows: 16-to 24-cm field of view, repetition time 2 RR intervals, echo delay time 20 ms (PDW) and 65 ms (T2W), image matrix 256ϫ160, echo train length 16 to 24, 1 NEX (number of excitations), no phase wrap, and spatial resolution of 0.63 to 1.41 mm 2 . The total duration was Ϸ40 minutes (actual scan time was Ϸ30 minutes).
Image Analysis
Follow-up MR images of same patient were reproduced by use of imaging planes with various identical anatomical landmarks (eg, pulmonary arteries; Figure 1 ). Data from each receiver coil (1 anterior, 2 posterior, and 1 transesophageal) were obtained individually, along with a composite image of all coils (combined). The composite image was used for all plaque and lumen analysis. The MR images were analyzed with Scion image 4.02 software (Scion Corporation) in a blinded manner at a different time than when the patients were imaged. T2W images were used for plaque analysis because this pulse sequence resulted in much better blood suppression, reducing flow artifacts at the plaque/blood interface while maintaining an adequate signal-to-noise ratio and resulting in better 
Reproducibility Studies and Statistical Methods
In 10 patients, we obtained a second MRI within 1 week of the initial MRI examination for reproducibility of plaque size measurements. These studies were also analyzed by 2 independent observers using the 2D and 3D methodologies described above. For purposes of assessing method reproducibility, we calculated the coefficient of variation (SDϫ100/mean) and intraclass correlation coefficient R. The latter coefficient is defined as the proportion of variance due to differences between subjects divided by the total variance. 25, 26 Data are expressed as meanϮSD. A paired Student t test was used to compare MRI and other parameters between baseline and 6 months. The generalized estimating equation approach was used to examine relationships between MRI and lipid parameters, with adjustment for potential confounding factors such as age, gender, and other factors. To examine whether MRI parameters are independently associated with lipid levels, an overall generalized estimating equation model included age, gender, family history, diabetes, smoking, and lipid parameters (including HDL, LDL, total cholesterol, and triglycerides). Those variables that failed to make a significant contribution to the model were eliminated in a stagewise manner, which yielded a final model. Univariate regression analysis was also used to study correlations between changes in lipid parameters and changes in MRI measures of plaque regression and vessel remodeling. All reported probability values are 2 sided, and a probability value of Ͻ0.05 was considered to indicate statistical significance.
Results
Patient Characteristics
Twenty-seven patients treated with simvastatin (20 to 80 mg) were followed up for 6 months after therapy initiation. There were no adverse events reported during the course of the study, and changes in liver function tests were clinically insignificant. Baseline demographic data are shown in the Table.
Serum Lipids
Baseline serum levels of total cholesterol (203Ϯ38 mg/dL) and LDL-C (125Ϯ32 mg/dL) decreased to 184Ϯ38 and 105Ϯ26 mg/dL, respectively, at 3 months and to 173Ϯ33 and 97Ϯ27 mg/dL, respectively, at 6 months (PϽ0.05) after the onset of statin therapy. HDL cholesterol changed from 48Ϯ15 to 50Ϯ14 mg/dL (PϭNS), and triglyceride levels changed from 146Ϯ80 to 133Ϯ61 mg/dL (PϭNS).
Reproducibility
The reproducibility of plaque size measurements by the combined surface and transesophageal technique was studied in 10 patients with documented atherosclerosis who returned to a repeat examination within 7 days of the initial study.
Cross-sectional plaque area measurements (2D) were closely correlated between study 1 and 2, with an intraclass correlation coefficient of Rϭ0.91 and a coefficient of variation of 23.9%. However, the most reproducible index of plaque size was 3D plaque volume, with an intraclass correlation coefficient of Rϭ0.97 and a coefficient of variation of 4.8%. Intraobserver and interobserver concordances were 0.91 and 0.81, respectively, for plaque volume. On the basis of these reproducibility studies, we calculated that changes in aortic plaque volume Ͼ4.6% can be considered as accurately measured by this MRI method.
MRI Plaque Regression
During the same period of time, plaque regression measured by MRI was significant for the entire group of patients. Plaque volume decreased from 3.3Ϯ1.4 cm 3 at baseline to 2.9Ϯ1.4 cm 3 at 6 months (12% reduction, PϽ0.02), whereas plaque area decreased from 1.63Ϯ0.7 cm 2 at baseline to 1.43Ϯ0.69 cm 2 (PϽ0.02), which reflects a 12% reduction ( Figure 2 ). Concomitant changes in vessel luminal volume from 12.0Ϯ3.9 cm 3 at baseline to 12.2Ϯ3.7 cm 3 at 6 months were of borderline significance (PϽ0.06; Figure 3 ), whereas changes in cross-sectional luminal area for the group as a whole were not statistically significant (from 5.97Ϯ1.8 to 6.05Ϯ1.8 cm 2 at 6 months). These results demonstrate that atherosclerotic plaque regression was detectable as early as 6 months after initiation of monitored simvastatin therapy. Multiple regression analysis was performed to examine whether these alterations were related to the magnitude of lipid-lowering changes observed during the same time period.
Demographics of the Study
Lipid Lowering and Plaque Regression Relationship
Plaque regression and vessel remodeling had a significant correlation with changes in LDL-C after adjustment for age, gender, family history, presence of coronary artery disease, diabetes, and changes in triglycerides and HDL cholesterol. Plaque regression, measured as reductions in plaque volume or plaque area, was directly proportional to LDL-C reduction (regression coefficients 7.07 [95% CI 1.3 to 12.9] and 0.41 [95% CI 0.13 to 0.69], respectively; PϽ0.02 and PϽ0.005, respectively). Concomitant increases in vessel lumen volume were inversely related to LDL-C reduction (regression coefficient 70.6 [95% CI 3.3 to 137.9], PϽ0.04), whereas for lumen area, the relationship was of borderline statistical significance (regression coefficient 2.9 [95% CI Ϫ0.5 to 6.38], PϽ0.10). When changes in LDL-C were correlated by single regression analysis against changes in vessel lumen, LDL-C reduction explained 25% of vessel lumen volume augmentation and 31% of vessel cross-sectional area increase in the first 6 months of simvastatin therapy (PϽ0.009 and PϽ0.003, respectively).
Discussion
This prospective clinical study demonstrates statin-induced plaque regression 6 months after the onset of MRI-monitored therapy. Simvastatin-induced LDL-C lowering was significantly correlated to plaque volume reduction and inversely correlated with arterial reverse remodeling associated with plaque regression, even after correction for other confounding variables. Finally, we also document the greater reproducibility of plaque volume versus plaque area assessment as a measure of regression of aortic atherosclerosis. Several previous studies have demonstrated the effect of lipid-lowering therapy in preventing plaque progression 11 relative to individuals unexposed to the intervention being tested. Other studies have documented actual regression of the atherosclerotic process expressed as an increase in angiographic vessel lumen 6 or a reduction in arterial wall thickness, 10,21 plaque area, 13 or plaque volume. 15 In the case of statin-induced atherosclerotic plaque modulation, these effects have been consistently reported after at least 1 year of therapy. 6, 8, 10, 11, 13, 16 Temporal differences in the onset of documented plaque regression relative to the present study can be explained by differences in methods, type or magnitude of statin therapy, or the target study population. Previous studies using luminal changes 6 or changes in plaque thickness measured in the carotid or femoral arteries 10, 11 may have had to wait a longer period of time before the biological effect could be detected. Similarly, less intensive statin regimens may have taken longer to produce differences in plaque thickness or vessel lumen. A previous prospective study using MRI found no evidence of plaque regression at 6 months but documented changes in plaque area measured in the aorta and carotid arteries 1 year after the onset of an identical regimen of simvastatin therapy. 13 In the present study, reductions in plaque volume and plaque area could be documented at the 6-month time point from studies performed in the aorta only and with somewhat different MRI methods. In addition, whereas only 1 target per patient was used in the present study, multiple targets were used in the previous study, which could have weighted its results toward nonrespondents or patients taking lower doses of simvastatin. However, despite methodological differences, it is also possible that the different time courses of plaque regression resulted from differences in the lipid-lowering responses among different groups of patients enrolled in the 2 studies. In the present study, plaque regression at 6 months was significantly correlated to LDL-C lowering. Participants in the present study also had significant baseline atherosclerosis, as suggested by the clinical characteristics shown in the Table. It is also possible that the time course and magnitude of plaque regression are directly proportional or easier to detect in patients with greater baseline burden, as suggested by studies in patients with as opposed to those without familial hypercholesterolemia, 10 as well as studies using the femoral wall thickness as opposed to carotid wall thickness measured by ultrasound. 10, 16, 27 Our understanding of atherosclerotic plaque regression is largely derived from pathological studies performed in experimental animals 21,28 -31 and humans. 14, 32 There is a large body of evidence indicating that atherosclerotic plaque lipid content is depleted with plasma cholesterol reduction 14 and that such reduction can be monitored experimentally by MRI. 21 Furthermore, concomitant reductions in plaque size and cholesterol levels have been documented in experimental studies without changes in collagen content. Therefore, plaque size reduction is likely to occur in response to reabsorption of lipids from the atherosclerotic plaque. 6 The results from the present study support this concept, given that a significant amount of regression effect seen at the 6-month time point was associated with changes in LDL-C reduction. They are also consistent with results from pathological studies that showed statin-induced atherosclerosis regression as early as 3 months after the initiation of therapy 14 and in part explain the salutary effects of statin therapy in terms of clinical outcomes 16 weeks after an index acute coronary syndrome, as documented in the Myocardial Ischemia Re- duction with Aggressive Cholesterol Lowering (MIRACL) study. 20
Methodological Considerations
The data presented in the present study, as in the reports by Corti et al, 13 originate from a clinical trial comparing high 80 mg/d versus 20 mg/d simvastatin therapy and therefore comprise patients randomized to both arms of the trial; however, MRI data analysis was performed by blinded observers relative to all other study variables. Furthermore, in the study by Corti et al, 13 vessel wall and lumen areas were measured in 28 nonatherosclerotic arterial wall segments at baseline and 1 year after therapy without any detectable changes. The TEMRI technique has been validated in autopsy studies, 23, 24 and its contribution to the combined approach has been quantified in previous work. 33 The present study also documents the superiority of plaque volume (intraclass correlation coefficient Rϭ0.97 and coefficient of varia-tionϭ4.8%) relative to plaque area (Rϭ0.91 and coefficient of variationϭ23.9%). Measurement of plaque area per slice is more dependent on the exact repositioning of the slices, whereas volume measurements tolerate subtler errors caused by misregistration.
Our study should be interpreted in light of certain limitations. The sample size is small, although the statistical testing shows that the results are significant results. The TEMRI technique is a semi-invasive procedure and therefore demands some further safety considerations, although none of the patients experienced any adverse effects, and all tolerated the procedure well without any sedation or anesthesia. Because of too few discrete plaques with discernible components, plaque characterization was not attempted during analysis. The field of view, although relatively large, was individually adjusted per patient (16 to 24 cm) according to their body habitus, and the parameters were consistent for the same patients during follow-up imaging. Another limiting factor was that fat suppression was not used for T2W images, which could obscure 1 side of the vessel wall. Finally, even though the reproducibility of plaque assessment is excellent (rϭ0.95), it is possible that the assessment error might be in the realm of statistically important events in patients with less severe disease, in whom this technique might be very helpful.
Conclusions
We demonstrate plaque regression 6 months after the onset of simvastatin therapy in patients with documented atherosclerosis. There appears to be a significant correlation between statin-induced lipid lowering and plaque regression, as well as reverse remodeling characterized by cross-sectional luminal increase. The study also demonstrates the feasibility of monitoring alterations of atherosclerotic plaque size by a novel MRI approach that enhances the surface MRI method by the placement of an additional transesophageal antennareceiver coil. Further studies are needed to examine the possibility that statin-induced regression can occur within the first 6 months of therapy, as well as its dependence on dose and magnitude of the disease process, before therapy initiation.
